1. Sanofi India bets big on insulin and specialty care after restructuring

Sanofi India bets big on insulin and specialty care after restructuring

Business

  • Sanofi India managing director Deepak Arora says the company is focusing on insulin and specialty-care medicines after restructuring.
  • Sanofi's insulin portfolio grew 14% in the September quarter, contributing around 60% of the company's revenue.
  • • Deepak Arora said public-sector insulin sales jumped 85% as Sanofi expanded supplies to government hospitals and healthcare programmes.
  • Sanofi plans new specialty-care launches, including Qfitlia, a haemophilia treatment expected to launch in India next year.

Source: moneycontrol.com

Get 100 stories a day on the app Read, watch & listen · Free on iOS & Android

Newer

Older